Skip to content

Study · Randomized controlled trial · n = 15 · 2012

4 results

Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.

Feifel D, Macdonald K, Cobb P, Minassian A

Schizophrenia research8 Jun 2012Cited by 92 (Europe PMC)

PMID22682705 (opens in a new tab)DOI10.1016/j.schres.2012.05.018 (opens in a new tab)PepBankPUB-22682705
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, adjunctive oxytocin improved total recall on trials 1-5 of the CVLT compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin added to usual treatment gave better verbal recall scores than placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseCVLT total recall trials 1-5
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    total Recall trials 1-5 (p=0.027)
    2 context sentences
    Summary · context
    As part of a previously reported trial of chronic adjunctive oxytocin in schizophrenia, we measured its effect on two cognitive tests: the CVLT (California Verbal Learning Test) and the LNS (Letter Number Sequence).
    Summary · context
    Tests were performed at baseline and after 3 weeks of treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, adjunctive oxytocin improved short delayed free recall on the CVLT compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin added to usual treatment gave better short delayed recall than placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseCVLT short delayed free recall
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    short delayed free recall (p=0.032)
    2 context sentences
    Summary · context
    As part of a previously reported trial of chronic adjunctive oxytocin in schizophrenia, we measured its effect on two cognitive tests: the CVLT (California Verbal Learning Test) and the LNS (Letter Number Sequence).
    Summary · context
    Tests were performed at baseline and after 3 weeks of treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, adjunctive oxytocin improved total recall discrimination on the CVLT compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin added to usual treatment gave better recall discrimination scores than placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseCVLT total recall discrimination
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    total recall discrimination (p=0.020)
    2 context sentences
    Summary · context
    As part of a previously reported trial of chronic adjunctive oxytocin in schizophrenia, we measured its effect on two cognitive tests: the CVLT (California Verbal Learning Test) and the LNS (Letter Number Sequence).
    Summary · context
    Tests were performed at baseline and after 3 weeks of treatment.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In people with schizophrenia, adjunctive oxytocin did not change Letter Number Sequence performance compared with placebo.

    In plain wordsIn people with schizophrenia, oxytocin added to usual treatment did not change a working memory test score compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeLetter Number Sequence (LNS) performance
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    In contrast we found no difference between placebo and oxytocin on LNS performance.
    2 context sentences
    Summary · context
    As part of a previously reported trial of chronic adjunctive oxytocin in schizophrenia, we measured its effect on two cognitive tests: the CVLT (California Verbal Learning Test) and the LNS (Letter Number Sequence).
    Summary · context
    Tests were performed at baseline and after 3 weeks of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedNot applicableResults postedNCT00506909

Oxytocin Add on Study for Stable Schizophrenic Patients

David Feifeln = 21Mar 2008 to Mar 2014

Schizophrenia

Trial pageClinicalTrials.govUpdated 25 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.